Abstract:<h3> Background</h3><p>Polycystic ovary syndrome (PCOS) has a prevalence of 8‐13%. Given the prevalence, diverse health impacts and variation in care, rigorous evidence‐based guidelines are needed in PCOS management. This systematic review with meta‐analyses aims to investigate the effect of the combined oral contraceptive pill (COCP) and/or metformin in the management of hormonal and clinical features of PCOS, to inform international guidelines.</p><h3> Methods</h3><p>Electronic databases were searched systematically from inception until 11 January 2017 to inform the guideline process. Eligible studies were randomized controlled trials (RCTs) which investigated the effect of COCPs and/or metformin alone or combined on hormonal and clinical features in women with PCOS. Outcomes were prioritised as critical for informing a decision about an intervention or important or not important, according to GRADE. Articles were assessed by one author against selection criteria, in consultation with a second author. Data were double extracted independently by four authors, and data quality appraisal completed. Meta‐analyses were conducted, where appropriate.</p><h3> Results</h3><p>Fifty‐six studies were eligible for inclusion. Outcomes prioritised by women and health professionals included: irregular cycles, insulin resistance, weight, BMI, thromboembolic events and gastrointestinal effects. In low quality evidence in adolescents, meta‐analyses demonstrated that metformin was better than COCP for BMI (mean difference (MD) −4.02 [−5.23, −2.81], p <0.001); and COCP was better than metformin for menstrual regulation (MD ‐0.19 [‐0.25, ‐0.13], p <0.00001). In low quality evidence in adults, meta‐analyses demonstrated that metformin was better than placebo for BMI (MD ‐0.48 [‐0.94, ‐0.02], p= 0.04); metformin was better than COCP for fasting insulin (MD 4.00 [2.59, 5.41], p= 0.00001), whereas COCP was better than metformin for irregular cycles (MD 12.49 [1.34, 116.62], p= 0.03). COCP alone was better than the combination with an anti‐androgen for BMI (MD ‐3.04 [‐5.45, ‐0.64], p= 0.01). Metformin was associated with generally mild gastrointestinal adverse events. Differences in statistical significance were observed when outcomes were sub‐grouped by BMI.</p><h3> Conclusions</h3><p>This review identified that COCP therapy has benefits for management of hyperandrogenism and menstrual regulation. Metformin combined with the COCP may be useful for management of metabolic features. There is minimal evidence of benefits of adding an anti‐androgen to COCP therapy.</p><p>Metformin alone has benefits for adult women for management of weight, hormonal, and metabolic outcomes, especially for women with BMI≥25 kg/m². There is inadequate evidence to suggest the optimal COCP formulation, or dosing regimen and formulation of metformin.</p><p>This article is protected by copyright. All rights reserved.</p>

Metformin for the treatment of the polycystic ovary syndrome

Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

The use of metformin in women with polycystic ovary syndrome: an updated review

Update on the Therapeutic Effects of Metformin in the Treatment of Polycystic Ovary Syndrome

Insulin Resistance, Polycystic Ovary Syndrome and Metformin

Effect of metformin combined therapy in patients with polycystic ovary syndrome

Polycystic ovary syndrome: treatment strategies and management

How to correctly understand the effect of metformin in the treatment of polycystic ovary syndrome

Polycystic Ovary Syndrome: Fertility Management

Efficacy of metformin combined with vitamin D in the treatment of polycystic ovarian syndrome: A meta-analysis

Therapeutic Effect of Metformin on Patients with Polycystic Ovary Syndrome with Normal Insulin Sensitivity: A Retrospective Study

Pharmacological management of polycystic ovary syndrome

The Effects of Metformin and Myo-Inositol on Hyperandrogenism, Insulin Sensitivity, and Fertility in Polycystic Ovary Syndrome: A Literature Review

Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta‐analyses

Treatment strategies for women with polycystic ovary syndrome

Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis

Efficacy of Metformin for Polycystic Ovary Syndrome:Evidence-based Evaluation

[Advance in treatment of polycystic ovary syndrome]

Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice

Polycystic ovary syndrome and infertility: an update